EP1638557A4 - Inhibiteurs de la glycogene synthase kinase-3 - Google Patents

Inhibiteurs de la glycogene synthase kinase-3

Info

Publication number
EP1638557A4
EP1638557A4 EP04744910A EP04744910A EP1638557A4 EP 1638557 A4 EP1638557 A4 EP 1638557A4 EP 04744910 A EP04744910 A EP 04744910A EP 04744910 A EP04744910 A EP 04744910A EP 1638557 A4 EP1638557 A4 EP 1638557A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
glycogen synthase
synthase kinase
kinase
glycogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04744910A
Other languages
German (de)
English (en)
Other versions
EP1638557A2 (fr
Inventor
Hagit Eldar-Finkelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tel Aviv University Future Technology Development LP
Original Assignee
Tel Aviv University Future Technology Development LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tel Aviv University Future Technology Development LP filed Critical Tel Aviv University Future Technology Development LP
Publication of EP1638557A2 publication Critical patent/EP1638557A2/fr
Publication of EP1638557A4 publication Critical patent/EP1638557A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
EP04744910A 2003-06-27 2004-06-27 Inhibiteurs de la glycogene synthase kinase-3 Ceased EP1638557A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48271903P 2003-06-27 2003-06-27
US52849503P 2003-12-11 2003-12-11
PCT/IL2004/000570 WO2005000192A2 (fr) 2003-06-27 2004-06-27 Inhibiteurs de la glycogene synthase kinase-3

Publications (2)

Publication Number Publication Date
EP1638557A2 EP1638557A2 (fr) 2006-03-29
EP1638557A4 true EP1638557A4 (fr) 2007-11-07

Family

ID=33555590

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04744910A Ceased EP1638557A4 (fr) 2003-06-27 2004-06-27 Inhibiteurs de la glycogene synthase kinase-3

Country Status (6)

Country Link
EP (1) EP1638557A4 (fr)
JP (1) JP2007527859A (fr)
KR (1) KR20060018902A (fr)
CN (1) CN1838954B (fr)
CA (1) CA2530111A1 (fr)
WO (1) WO2005000192A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049709A1 (fr) 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Inhibiteurs de glycogene synthase kinase-3
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
EP1569956B1 (fr) 2002-12-12 2014-02-26 Tel Aviv University Future Technology Development L.P. Inhibiteurs de la glycogene synthase kinase-3
AU2005234687A1 (en) * 2003-06-27 2005-12-08 Tel Aviv Universtiy Future Technology Development L.P. Glycogen Synthase Kinase-3 Inhibitors
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques
CA2786314A1 (fr) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Nouveaux derives benzimidazole cycliques utiles comme agents antidiabetiques
EP2668199B1 (fr) 2011-01-27 2017-09-06 Ramot at Tel Aviv University, Ltd. Inhibiteurs de glycogène synthase kinase-3
WO2012101601A1 (fr) 2011-01-27 2012-08-02 Ramot At Tel-Aviv University Ltd. Inhibiteurs de glycogène synthase kinase 3
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP3013850B1 (fr) 2013-06-24 2018-07-25 Ramot at Tel-Aviv University Ltd. Inhibiteurs de glycogène synthase kinase-3
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2018106518A1 (fr) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Composés hétérocycliques antidiabétiques
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB781806A (en) * 1955-04-29 1957-08-28 Roche Products Ltd Organic phosphate, salts thereof, and process for the manufacture thereof
WO1998005961A1 (fr) * 1996-08-01 1998-02-12 Isis Pharmaceuticals, Inc. Composes contenant une pluralite de substituants azotes
WO2002016318A1 (fr) * 2000-08-21 2002-02-28 Pacific Corporation Nouveaux derives de thiourea et compositions pharmaceutiques renfermant ceux-ci

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB785457A (en) * 1954-09-10 1957-10-30 Ici Ltd Phosphated metallisable azo dyestuffs
JPS49125510A (fr) * 1973-04-11 1974-12-02
JPS57212704A (en) * 1981-06-24 1982-12-27 Fujikura Ltd Electric cable
JPS5871937A (ja) * 1981-10-23 1983-04-28 Adeka Argus Chem Co Ltd ハロゲン含有樹脂組成物
JPS63250063A (ja) * 1987-04-03 1988-10-17 Matsushita Electric Ind Co Ltd 亜鉛アルカリ電池
US6441140B1 (en) * 1998-09-04 2002-08-27 Cell Signaling Technology, Inc. Production of motif-specific and context-independent antibodies using peptide libraries as antigens
WO2001049709A1 (fr) * 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Inhibiteurs de glycogene synthase kinase-3
CA2451994C (fr) * 2001-07-16 2011-03-22 Teijin Limited Catalyseur destine a la production de polyester et procede de production de polyester faisant intervenir ce catalyseur

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB781806A (en) * 1955-04-29 1957-08-28 Roche Products Ltd Organic phosphate, salts thereof, and process for the manufacture thereof
WO1998005961A1 (fr) * 1996-08-01 1998-02-12 Isis Pharmaceuticals, Inc. Composes contenant une pluralite de substituants azotes
WO2002016318A1 (fr) * 2000-08-21 2002-02-28 Pacific Corporation Nouveaux derives de thiourea et compositions pharmaceutiques renfermant ceux-ci

Also Published As

Publication number Publication date
WO2005000192A2 (fr) 2005-01-06
KR20060018902A (ko) 2006-03-02
WO2005000192A3 (fr) 2005-06-02
EP1638557A2 (fr) 2006-03-29
JP2007527859A (ja) 2007-10-04
CN1838954B (zh) 2013-01-16
CN1838954A (zh) 2006-09-27
CA2530111A1 (fr) 2005-01-06

Similar Documents

Publication Publication Date Title
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
GB2424882B (en) Selective kinase inhibitors
IL175568A0 (en) Azole-based kinase inhibitors
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
AP2006003620A0 (en) Imidazopyrazine tyroshine kinase inhibitors
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL173139A0 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
PL373649A1 (en) Kinase inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
HK1091838A1 (en) Gfat inhibitors
SI1569907T1 (sl) Na nikotinamidu osnovani kinazni inhibitorji
AU2625201A (en) Glycogen synthase kinase-3 inhibitors
EP1558609A4 (fr) Inhibiteurs de kinase
GB2403757B (en) Hydrate Inhibiting well fluids
EP1682547A4 (fr) Inhibiteurs polymerase rsv
EP1638557A4 (fr) Inhibiteurs de la glycogene synthase kinase-3
EP1569907A4 (fr) Inhibiteurs de kinase a base de nicotinamide
GB0324598D0 (en) Cyclin groove inhibitors
GB0312619D0 (en) Complement inhibitors
GB0300607D0 (en) Inhibitors
GB0329869D0 (en) Inhibitors
AU157608S (en) Insert
GB0327386D0 (en) Complement inhibitors
GB0303924D0 (en) Modified nucleotides
GB0327146D0 (en) Modified nucleotides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051220

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20071008

R17P Request for examination filed (corrected)

Effective date: 20051220

R17P Request for examination filed (corrected)

Effective date: 20051220

17Q First examination report despatched

Effective date: 20100311

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20131205